Provided by Tiger Fintech (Singapore) Pte. Ltd.

NLS Pharmaceutics Ltd.

7.62
0.0000
Volume:- -
Turnover:- -
Market Cap:32.40M
PE:- -
High:7.62
Open:7.62
Low:7.62
Close:7.62
52wk High:7.62
52wk Low:0.7400
Shares:4.25M
Float Shares:3.42M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(LYR):-2.6288
ROE:-862.92%
ROA:-75.98%
PB:11.50
PE(LYR):-2.90

Loading ...

NLS Pharmaceutics AG trading halted, news pending

TIPRANKS
·
Yesterday

BRIEF-NLS Pharmaceutics Ltd. And Kadimastem Ltd. Announce Completion Of Merger

Reuters
·
Yesterday

NLS Pharmaceutics and Kadimastem Complete Merger to Form NewcelX

TIPRANKS
·
Yesterday

Press Release: NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger

Dow Jones
·
Yesterday

NLS Pharmaceutics and Kadimastem Continue ITOL-102 Diabetes Program Post-Merger

TIPRANKS
·
Oct 29

NLS Pharmaceutics and Kadimastem Secure Continued BIRD Foundation Support Following Merger

Reuters
·
Oct 29

NLS Pharmaceutics: Following Merger Between Co and Kadimastem,Combined Co Will Continue to Advance Itol-102 Program

THOMSON REUTERS
·
Oct 29

BRIEF-Nls Pharmaceutics Announces 1-for-10 Reverse Share Split And Name Change In Connection With Proposed Merger With Kadimastem

Reuters
·
Oct 29

NLS Pharmaceutics - Reverse Split Effective in Switzerland on October 30, 2025

THOMSON REUTERS
·
Oct 29

NLS Pharmaceutics - Common Shares to Trade on Nasdaq as Ncel Under New Name Newcelx Ltd

THOMSON REUTERS
·
Oct 29

NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection With Proposed Merger With Kadimastem

THOMSON REUTERS
·
Oct 29

Press Release: NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares

Dow Jones
·
Oct 29

NLS Pharmaceutics and Kadimastem Set October 30 Closing for Merger and Nasdaq Listing as NewCelX

Reuters
·
Oct 29

NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration Between Kadimastem and Targetgene to Advance Next-Generation Gene-Edited Cell Therapies

THOMSON REUTERS
·
Oct 27

Press Release: NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies

Dow Jones
·
Oct 27

Press Release: NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025

Dow Jones
·
Oct 23

Kadimastem Ltd Subsidiary of NLS Pharmaceutics Ltd Reports Six Month Loss of 11204 Thousand USD on No Reported Sales or Revenues with Increased Net Loss and No EPS Data Provided

Reuters
·
Oct 10

NLS Pharmaceutics H1 EPS $(1.05) Up From $(1.94) YoY

Benzinga
·
Oct 06

NLS Pharmaceutics Shareholders Approve Merger with Kadimastem, Paving Way for Launch of NewCelX on Nasdaq

Reuters
·
Sep 30

BRIEF-NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting

Reuters
·
Sep 30